2010

19-July-2010:  Amira Pharmaceuticals Hits Two Development Milestones Related to FLAP Inhibitor Program Amira Pharmaceuticals, Inc. announced today that its FLAP (5-lipoxygenase-activating protein) program, which is partnered with GlaxoSmithKline, has achieved two clinical development milestones. <PDF>

13-July-2010:  Amira Announces AM103 and AM803 Patent Grant in the UnitedKingdom
Amira Pharmaceuticals, Inc. today announced that the U.K. Intellectual Property Office has granted patent number GB2431927, titled, “5-Lipoxygenase Activating Protein (FLAP) Inhibitors,” which includes coverage of Amira’s AM103 and AM803 FLAP inhibitors for the treatment of respiratory disorders. <PDF>

26-May-2010:  Amira Announces Second DP2 Antagonist Patent Grant in the United Kingdom Amira Pharmaceuticals, Inc. today announced that the U.K. Intellectual Property Office has granted patent number GB2461629, titled, “HETEROALKYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS,” which includes coverage of Amira’s AM461 DP2 receptor antagonist. <PDF>

6-May-2010:  Anti-Fibrotic Data from Amira Pharmaceuticals’ LPA1 Receptor Antagonist Program Published in the British Journal of Pharmacology Amira Pharmaceuticals, Inc. announced today that preclinical data from its LPA1 receptor antagonist program has been published in the British Journal of Pharmacology. ” <PDF>

21-April-2010:  Amira Pharmaceuticals Announces Patent Grant in United Kingdom Amira Pharmaceuticals, Inc. today announced that the U.K. Intellectual Property Office has granted it patent number GB2460597 titled “N,NDISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS.” <PDF>

10-February-2010:  Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma Amira Pharmaceuticals, Inc. announced today that their collaborators, Andrew Tager, M.D. and Flavia V. Castelino, M.D. of Massachusetts General Hospital, Harvard Medical School, will present a preclinical proof-of-concept study which demonstrates that the bioactive lipid lysophosphatidic acid (LPA), through its high affinity LPA1 receptor, is an important mediator of fibrogenesis in the bleomycin mouse model of scleroderma. <PDF>

11-January-2010:  Amira Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference Amira Pharmaceuticals, Inc., a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease, announced today that Robert Baltera, Chief Executive Officer, will present a company overview at the 28th Annual J.P. Morgan Healthcare Conference. <PDF>

7-January-2010:  Amira Pharmaceuticals Achieves Development Milestone Related to FLAP Inhibitor Program Amira Pharmaceuticals, Inc. announced today that it has achieved another development milestone in its FLAP program, which is partnered with GlaxoSmithKline. <PDF>

2009

3-December-2009:  Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM461, A Back-Up to Amira’s Lead DP2 Antagonist, AM211. Results Demonstrate Positive Proof of Mechanism AAmira Pharmaceuticals, Inc. announced today initial positive data from a Phase 1 clinical study of AM461, the Company’s second oral selective antagonist of the DP2 (also known as CRTH2) receptor. <PDF>

27-October-2009:  Amira Pharmaceuticals to Present at the BIO Investor Forum in San Francisco Amira Pharmaceuticals, Inc., a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease, announced today that Robert Baltera, Chief Executive Officer, will present a company overview at the 8th Annual BIO Investor Forum. The presentation is scheduled for 2:30 p.m. PDT on Thursday, October 29, at the Palace Hotel in San Francisco, Calif. <PDF>

22-October-2009:  Amira Pharmaceuticals to Present at the BIOCOM Investor Conference in San Diego Amira Pharmaceuticals, Inc., a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease, announced today that Robert Baltera, Chief Executive Officer, will present at the 4th Annual BIOCOM Investor Conference. <PDF>

6-October-2009:  Amira Pharmaceuticals to Present at Montgomery Healthcare Conference Amira Pharmaceuticals, Inc., a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease, announced today that Robert Baltera, Chief Executive Officer, will present a company overview at the Montgomery Healthcare Conference 2009 in Menlo Park, Calif., today. <PDF>

3-September-2009:  Amira Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference Amira Pharmaceuticals, Inc., a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease, announced today that Robert Baltera, Chief Executive Officer, will present a company overview at the Thomas Weisel Partners Healthcare Conference. <PDF>

18-August-2009:  Amira Pharmaceuticals Submits IND for Second DP2 Antagonist, AM461 Amira Pharmaceuticals, Inc. announced today the submission of an Investigational New Drug application (IND) of AM461, its internally-discovered, oral drug candidate for the treatment and control of inflammatory and allergic disease linked to the arachidonic acid pathway, to the U.S. Food and Drug Administration. <PDF>

30-June-2009:  Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM211, A Novel Product Candidate for the Treatment of Respiratory Diseases. Results Demonstrate Positive Proof of Mechanism Amira Pharmaceuticals, Inc. announced today initial positive data from a Phase 1 clinical study of AM211, the company’s oral selective antagonist of the DP2 (also known as CRTH2) receptor. <PDF>

15-June-2009:  Amira Pharmaceuticals to Present Preclinical Data from LPA1 Receptor Antagonist Program at FASEB Summer Research Conference Amira Pharmaceuticals, Inc. announced today that it will present preclinical data from its LPA1 receptor antagonist program on June 30, 2009 at the Federation of American Societies for Experimental Biology (FASEB) Summer Research Conference in Carefree, Arizona.<PDF>

20-April-2009:  Amira initiates Phase I clinical trial of novel DP2 antagonist. Trial will evaluate safety, proof of mechanism of a potential oral antagonist for the treatment of asthma and COPD. Amira Pharmaceuticals, Inc., announced today the initiation of a Phase I clinical study of AM211, its internally discovered oral drug candidate for the treatment and control of inflammatory and allergic diseases linked to the arachidonic acid pathway.<PDF>

8-Jan-2009:  Amira Pharmaceuticals, Inc. expands its Scientific Advisory Board and appoints Dr. Paul Anderson, Professor Jerold Chun and Professor Andrew Tager. Amira Pharmaceuticals, a small molecule pharmaceutical company focused on the discovery and early development of compounds to treat inflammatory diseases, today announced the appointment of Dr. Paul Anderson, Professor Jerold Chun and Professor Andrew Tager to its Scientific Advisory Board.<PDF>

6-Jan-2009:  Amira announces the successful completion of GLP toxicity studies for a novel DP2 antagonist. Lead candidate on track for IND submission first half of 2009.Amira Pharmaceuticals, Inc. announced AM211, Amira's internally discovered oral drug candidate for the treatment and control of inflammatory and allergic diseases linked to the arachidonic acid pathway, is on target for submission of an IND to the U.S. Food and Drug Administration (FDA) by mid-2009 following the successful completion of Good Laboratory Practices (GLP) toxicity studies.<PDF>

2008

9-June-2008:  Amira Pharmaceuticals Hires Industry Veteran for CFO PositionAmira Pharmaceuticals, a small molecule pharmaceutical company focused on the discovery and development of compounds to treat inflammatory diseases, announced the hiring of Michael V. Swanson as the company’s Chief Financial Officer.<PDF>

2-June-2008:  Amira Pharmaceuticals achieves milestones in FLAP inhibitor program with GlaxoSmithKline GSK exercises option for AM803, a FLAP inhibitor which recently completed phase I studies Amira Pharmaceuticals today announced that under the terms of a worldwide exclusive agreement entered into in Feb 2008, GlaxoSmithKline (GSK) will exercise its right to a second FLAP compound, AM803<PDF>

31-March-2008:  Dr. Dennis Fenton and Dr. Steve Kaldor Join Amira Board of Directors Amira Pharmaceuticals, a small molecule pharmaceutical company focused on the discovery and development of compounds to treat inflammatory disease, today announced the appointment of two additional members to its board of directors: Dennis M. Fenton, Ph.D. and Stephen W. Kaldor, Ph.D. <PDF>

4-February-2008:  Amira Pharmaceuticals and GlaxoSmithKline enter global agreement for FLAP inhibitor program. Deal follows positive phase I data from novel product candidate AM103 for the oral treatment of respiratory disease Amira Pharmaceuticals and GlaxoSmithKline today announced they have entered into a worldwide exclusive agreement to develop, manufacture and commercialize FLAP (5-Lipoxygenase Activating Protein¬) inhibitors for the treatment of respiratory and cardiovascular disease.

Under the terms of the agreement GSK will be granted an exclusive, worldwide license to develop, manufacture and commercialize Amira’s FLAP inhibitors, including AM103 and other compounds within the current development program. In the event that all potential development and regulatory milestones are successfully achieved, Amira could receive up to US $425 million in upfront and milestone payments. In addition, Amira will be entitled to receive tiered royalty payments based on worldwide net sales and commercial sales milestones. <PDF>

2007

1-November-2007:  Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease Amira Pharmaceuticals, Inc. announced completion of the company’s Phase 1 clinical trial of AM103, Amira's internally discovered oral drug candidate for the treatment of inflammatory diseases linked to the leukotriene pathway. Amira also announced the start of a Phase 1 trial for AM803, a second oral drug candidate that targets the same inflammatory response. <PDF>

1-November-2007:  Amira Pharmaceuticals Appoints First Vice President of Development  Amira Pharmaceuticals, a small molecule pharmaceutical company focused on the discovery and development of compounds to treat inflammatory disease linked to the eicosanoid pathway, today announced the appointment of Isabelle Raizon-Ounis, M.D., as vice president of development. <PDF>

1-October-2007:  Amira Pharmaceuticals Announces Appointment of Chief Business Officer Amira Pharmaceuticals, a small molecule pharmaceutical company focused on the discovery and development of compounds to treat inflammatory disease linked to the eicosanoid pathway, today announced the appointment of Hari Kumar, Ph.D, as the company’s chief business officer, effective immediately. <PDF>

Next